1. Volume 56, Issue 3, Pages 534-543 (September 2009)
Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With α-Blockers 
Christopher Chapple, Sender Herschorn, Paul Abrams, Franklin Sun, Marina Brodsky, Zhonghong Guan 
European Urology 
Volume 56, Issue 3, Pages (September 2009)
DOI: /j.eururo
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1 Disposition of subjects assigned to study treatment.
ER=extended release.
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Effect of treatment on bladder diary variables, showing least squares mean ± SE change from baseline for number of micturitions and urgency episodes per 24h, with daytime and nocturnal events, and UUI episodes per 24h recorded in bladder diaries.
PBO=placebo; TER=tolterodine extended release; UUI=urgency urinary incontinence.
*p<0.05.
†p<0.01.
‡p≤0.001 for treatment differences based on an analysis of covariance model with terms for country, treatment, and treatment-by-country interaction with the baseline value as a covariate.
UUI episodes were present in only 15% of enrolled subjects.
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

4. Fig. 3
Effect of treatment on International Prostate Symptom Score, showing least squares mean±SE change from baseline for total index score, storage subscale, voiding subscale, and quality of life (QoL) items.
PBO=placebo; TER=tolterodine extended release.
*p= for treatment difference based on an analysis of covariance model with terms for country, treatment, and treatment-by-country interaction with the baseline value as a covariate.
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions

5. Fig. 4
Effect of treatment on Overactive Bladder Questionnaire scores, showing least squares mean±SE change from baseline for symptom bother scale, total Health-Related Quality of Life (HRQL) scale, and the coping, concern, sleep, and social interaction domains.
PBO=placebo; TER=tolterodine extended release.
*p=
†p= for treatment differences based on an analysis of covariance model with terms for country, treatment, and treatment-by-country interaction with the baseline value as a covariate.
European Urology  , DOI: ( /j.eururo )
Copyright © 2008 European Association of Urology Terms and Conditions